Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled study of CM-101 in primary sclerosing cholangitis
MOH_2020-07-19_009147Phase 2Not yet recruiting
- Sponsor
- Chemomab Therapeutics
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing CM-101 with Placebo (2 arms). Planned start Jun 2020; status: not yet recruiting.
02
Drugs
nebokitug
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on MOH_2020-07-19_009147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-19_009147.